JPMorgan Chase & Co. Has $9.18 Million Stock Holdings in CG Oncology, Inc. $CGON

JPMorgan Chase & Co. lifted its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON) by 321.3% during the 3rd quarter, Holdings Channel reports. The firm owned 227,879 shares of the company’s stock after purchasing an additional 173,785 shares during the quarter. JPMorgan Chase & Co.’s holdings in CG Oncology were worth $9,179,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Winthrop Capital Management LLC bought a new stake in CG Oncology in the second quarter worth approximately $38,000. Strengthening Families & Communities LLC bought a new position in shares of CG Oncology during the 3rd quarter worth approximately $40,000. PNC Financial Services Group Inc. grew its position in shares of CG Oncology by 15.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock worth $85,000 after buying an additional 433 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of CG Oncology by 159.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock valued at $182,000 after acquiring an additional 4,288 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in shares of CG Oncology in the 3rd quarter valued at $208,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

Analyst Upgrades and Downgrades

CGON has been the topic of a number of research reports. Royal Bank Of Canada boosted their target price on shares of CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $82.00 price target on shares of CG Oncology in a research note on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Truist Financial increased their price objective on shares of CG Oncology from $66.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Finally, HC Wainwright raised their target price on CG Oncology from $75.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $69.00.

CG Oncology Trading Up 2.5%

NASDAQ CGON opened at $61.88 on Friday. The company has a fifty day simple moving average of $52.44 and a 200 day simple moving average of $43.29. CG Oncology, Inc. has a 12-month low of $14.80 and a 12-month high of $63.58. The company has a market cap of $5.22 billion, a P/E ratio of -29.89 and a beta of 1.18.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.10. The business had revenue of $2.32 million for the quarter. Sell-side analysts predict that CG Oncology, Inc. will post -1.31 EPS for the current year.

Insider Activity at CG Oncology

In other news, Director James Mulay sold 11,145 shares of the business’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $52.47, for a total transaction of $584,778.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.40% of the stock is currently owned by insiders.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.